Company: ABBV
Filing Date: 2025-03-10
Form Type: PRE 14A
Source: 0001558370-25-002603
Chunk: 45

Company: AbbVie Inc.
Filing Date: 2025-03-10
Form: PRE 14A
Chunk 45
---
50 | 2025 Proxy Statement

| ​ | ​                      |
| ​ | EXECUTIVE COMPENSATION |

| ● | AbbVie does not include certain pay design features that may have the potential to encourage excessive risk-taking, such as: over-weighting toward annual incentives, highly leveraged payout curves, unreasonable thresholds or dramatic changes in payout opportunity at certain performance levels that may encourage inappropriate short-term business decisions to meet payout thresholds. In addition for 2024, a limit of 190% of target applies to any awards made under the NEO short-term incentive program. |

| ● | AbbVie makes equity awards and sets grant prices at the same time each year, at the compensation committee’s regularly scheduled meeting in February. In addition, AbbVie does not award discounted stock options or immediately vested equity awards to NEOs. |

| ● | AbbVie has robust stock ownership guidelines for its senior executives, which promotes alignment with stockholder interests, and other good governance equity practices such as anti-hedging and anti-pledging policies. |

| ● | AbbVie’s compensation committee has the ability to exercise downward discretion in determining annual incentive plan payouts. |

| ● | AbbVie’s compensation committee is required to clawback excess compensation in the event of a restatement, plus retains broad discretion to clawback compensation in the event of a material breach of the AbbVie Code of Business Conduct. |

| ● | AbbVie requires mandatory training on its code of conduct and policies and procedures to educate its employees on appropriate behaviors and the consequences of taking inappropriate actions. |

The risk assessment results were presented to the compensation committee by its independent compensation consultant.

2025 Proxy Statement |51

| ​                      | ​ |
| EXECUTIVE COMPENSATION | ​ |

Summary Compensation Table This section contains compensation information for AbbVie’s NEOs for the fiscal year ended December 31, 2024. The following table summarizes compensation awarded to, earned by and/or paid to AbbVie’s NEOs in connection with their service to AbbVie during 2024, 2023 and 2022, as applicable. The section of this proxy statement captioned “Compensation Plan Elements” describes in greater detail the information reported in this table.

| ​                               
 ​                               
 ​                               
 ​                               
 ​                               
 ​                               
 ​                               
 ​                               
 Name and Principal Position     | ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ 
 ​ |    ​ 
    ​ 
    ​ 
    ​